title: Acceptability of cancer chemoprevention trials: impact of the design.
abstract: BACKGROUND
  Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and risk/benefit balance is at best achieved through randomized clinical trials.
  
  
  METHODS
  At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to be involved in different kinds of preventive clinical trials.
  
  
  RESULTS
  Among the 851 respondents (58.2%), 228 (26.8%) agreed to participate in a hypothetical chemoprevention trial aimed at reducing the incidence of lung cancer and 116 (29.3%) of 396 women agreed to a breast cancer chemoprevention trial. Randomization would not restrain participation (acceptability rate: 87.7% for lung cancer and 93.0% for breast cancer). In these volunteers, short-term trials (1 year) reached a high level of acceptability: 71.5% and 73.7% for lung and breast cancer prevention respectively. In contrast long-term trials (5 years or more) were far less acceptable: 9.2% for lung cancer (OR=7.7 CI(95%) 4.4-14.0) and 10.5 % for breast cancer (OR=6.9 CI(95%) 3.2-15.8). For lung cancer prevention, the route of administration impacts on acceptability with higher rate 53.1% for a pill vs. 7.9% for a spray (OR=6.7 CI(95%) 3.6-12.9).
  
  
  CONCLUSIONS
  Overall healthy individuals are not keen to be involved in chemo-preventive trials, the design of which could however increase the acceptability rate.
authors.affiliation: Institut Paoli-Calmettes, Department of Oncogenetics Prevention and Screening Marseille France.
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Maisonneuve
authors.forename: Laetitia
authors.initials: L
authors.lastname: Huiart
authors.forename: Laetitia
authors.initials: L
authors.lastname: Rabayrol
authors.forename: Doug
authors.initials: D
authors.lastname: Horsman
authors.forename: Remi
authors.initials: R
authors.lastname: Didelot
authors.forename: Hagay
authors.initials: H
authors.lastname: Sobol
authors.forename: Francois
authors.initials: F
authors.lastname: Eisinger